Your clinician's ability to screen contraindications depends entirely on what you tell them
However, clinical trials investigating GLP-1RAs in diseases such as AD, PD, mild cognitive impairment, psychiatric disorders, and diabetes have yielded mixed results for cognitive and motor function
They've actually been around for quite a while in that capacity, but subsequent trials showed that, "Hey, these medications have substantial weight loss benefits, too." And so, now some are approved specifically for chronic weight management
And the skin concerns that accompany this level of weight change deserve a thoughtful, medically led response
GEP44 was developed based on extensive structureactivity relationship studies and earlier preliminary in vivo studies that demonstrated its greater efficacy at reducing both food intake and body weight compared to the agonist peptide, Ex-4, without triggering gastrointestinal distress (as assessed by kaolin intake and behavioral scoring as a proxy for nausea in rats and direct evidence of emesis in shrews) 16
